Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling.

Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Abstract Text:

Scott D Bembenek,John M Keith,Michael A Letavic,Richard Apodaca,Ann J Barbier,Lisa Dvorak,Leah Aluisio,Kirsten L Miller,Timothy W Lovenberg,Nicholas I Carruthers,Scott D Bembenek,John M Keith,Michael A Letavic,Richard Apodaca,Ann J Barbier,Lisa Dvorak,Leah Aluisio,Kirsten L Miller,Timothy W Lovenberg,Nicholas I Carruthers,

Currently, the only clinically effective treatment for Alzheimer's disease (AD) is the use of acetylcholinesterase (AChE) inhibitors. These inhibitors have limited efficacy in that they only treat the symptoms and not the disease itself. Additionally, they often have unpleasant side effects. Here we consider the viability of a single molecule having the actions of both an AChE inhibitor and histamine H(3) receptor antagonist. Both histamine H(3) receptor antagonists and AChE inhibitors improve and augment cholinergic neurotransmission in the cortex. However, whereas an AChE inhibitor will impart its effect everywhere, a histamine H(3) antagonist will raise acetylcholine levels mostly in the brain as its mode of action will primarily be on the central nervous system. Therefore, the combination of both activities in a single molecule could be advantageous. Indeed, studies suggest an appropriate dual-acting compound may offer the desired therapeutic effect with fewer unpleasant side effects [CNS Drugs2004, 18, 827]. Further, recent studies(2) indicate the peripheral anionic site (PAS) of AChE interacts with the beta-amyloid (betaA) peptide. Consequently, a molecule capable of disrupting this interaction may have a significant impact on the production of or the aggregation of betaA. This may result in slowing down the progression of the disease rather than only treating the symptoms as current therapies do. Here, we detail how the use of the available crystal structure information, pharmacophore modeling and docking (automated, manual, classical, and QM/MM) lead to the identification of an AChE inhibitor-histamine H(3) receptor antagonist. Further, based on our models we speculate that this dual-acting compound may interact with the PAS. Such a dual-acting compound may be able to affect the pathology of AD in addition to providing symptomatic relief.

Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Publishing Authors By Initials

SD Bembenek,JM Keith,MA Letavic,R Apodaca,AJ Barbier,L Dvorak,L Aluisio,KL Miller,TW Lovenberg,NI Carruthers,SD Bembenek,JM Keith,MA Letavic,R Apodaca,AJ Barbier,L Dvorak,L Aluisio,KL Miller,TW Lovenberg,NI Carruthers,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bioorganic & medicinal chemistry

VOLUME: 16

Page Numbers: 2968-73

Journal Abbreviation:

ISSN: 1464-3391

DAY: 25

MONTH: 12

YEAR: 2007

Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9413298

Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling.

AFFILIATION:

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bioorg Med Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling Related Publications

• 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.
• A cleavable propeptide influences Toxoplasma infection by facilitating the trafficking and secretion of the TgMIC2-M2AP invasion complex.
• A transient forward-targeting element for microneme-regulated secretion in Toxoplasma gondii.
• ATP-dependent sugar transport complexity in human erythrocytes.
• Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
• Broadening discussions of "safe" in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice.
• Caveat emptor (buyer beware).
• Discussion: the history of injectable silicone fluids for soft-tissue augmentation.
• Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores.
• Elderly patients with hypertension should retain 'special' status.
• Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid.
• Host cell manipulation by the human pathogen Toxoplasma gondii.
• Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid.
• Laboratory testing of spermicidal preparation.
• Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling.
• MARveling at parasite invasion.
• Mad cows, prions, and wrinkles.
• Malakoplakia: report of a case.
• Patient-reported outcomes with botulinum neurotoxin type A.
• Recent medicinal chemistry of the histamine H3 receptor.
• Reminders in echocardiography reports increased use of blockers in reduced left ventricular ejection fraction.
• Shrinking upper and lower eyelid skin with a novel radiofrequency tip.
• Some points in the diagnosis of labyrinthine vertigo and a survey of methods of treatment, medical and surgical.
• Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.
• The J-curve--it is clinically relevant?
• The diagnosis of late life hypogonadism.
• The evolution of botulinum neurotoxin type A for cosmetic applications.
• The organization of a community: community-based prevention of injecting drug use-related health problems.
• The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action.
• [Not Available.]